Antibodies
24 September 2013
TRACON Pharmaceuticals Initiates Phase 1b Study of TRC105 in Patients With Metastatic Renal Cell Carcinoma20 September 2013
ImmunoGen, Inc. Announces Positive Regulatory Decisions for Roche’s Kadcyla® in the European Union and Japan19 September 2013
Cangene Awarded Biodefence Contract for Anthrax Immune Globulin (AIGIV) by the U.S. Government19 September 2013
OncoMed Pharmaceuticals Initiates Phase 1b/2 Clinical Trial of Demcizumab (Anti-DLL4) in Combination with Paclitaxel in Ovarian Cancer17 September 2013
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer17 September 2013
MorphoSys Receives Two Phase 2 Milestone Payments from Janssen17 September 2013
European Commission Approves Genzyme’s Multiple Sclerosis Treatment Lemtrada™ (alemtuzumab)14 September 2013
FDA grants GSK and Genmab’s Arzerra® (ofatumumab) Breakthrough Therapy designation for previously untreated chronic lymphocytic leukaemia13 September 2013
Visterra Announces an Oral Presentation of VIS410 Data that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic Potential13 September 2013
FDA Advisory Committee Recommends Accelerated Approval of Genentech’s Perjeta for Neoadjuvant Use in HER2-Positive Early Stage Breast Cancer12 September 2013
arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.712 September 2013
Bristol-Myers Squibb Reports Results for Phase 3 Trial of Yervoy® (Ipilimumab) in Previously-Treated Castration-Resistant Prostate Cancer10 September 2013
Hospira’s Inflectra (infliximab) the first biosimilar monoclonal antibody to be approved in Europe10 September 2013
Theraclone Sciences Announces Initiation of Phase 2a Trial of TCN-202 for the Prevention of Human Cytomegalovirus Infection9 September 2013
Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential5 September 2013
Takeda’s New Investigational Drug Vedolizumab is Granted Priority Review Status by U.S. Food and Drug Administration for Ulcerative Colitis4 September 2013
XBiotech Announces it is Developing Therapy for MRSA3 September 2013
Baxter and Coherus Biosciences Announce Collaboration to Develop and Commercialize Biosimilars3 September 2013
Simultaneous Applications Submitted to FDA and EMA for Siltuximab for the Treatment of Multicentric Castleman Disease, a Rare Blood Disorder3 September 2013
Novartis receives EU approval for Ilaris® in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis2 September 2013
WILEX subsidiary Heidelberg Pharma signs license agreement for the development of Antibody Targeted Amanitin Conjugates (ATACs) with Roche2 September 2013
Amgen Presents Pooled Analysis Showing AMG 145 Significantly Reduced LDL Cholesterol In Over 1,200 PatientsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports